Nature Biotechnology

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants

Sylvia Rothenberger 1, 2
Daniel L. Hurdiss 3, 4
Marcel Walser 5
Francesca Malvezzi 5
Jennifer Mayor 1, 2
Sarah Ryter 2
Hector Moreno 1
Nicole Liechti 2
Andreas Bosshart 5
Chloe Iss 5
Valérie Calabro 5
Andreas Cornelius 5
Tanja Hospodarsch 5
Alexandra Neculcea 5
Thamar Looser 5
Anja Schlegel 5
Simon Fontaine 5
Denis Villemagne 5
Maria Paladino 5
Schiegg Dieter 5
Susanne Mangold 5
Christian Reichen 5
Filip Radom 5
Yvonne Kaufmann 5
Doris Schaible 5
Iris Schlegel 5
Christof ZITT 5
Gabriel Sigrist 5
Marcel Straumann 5
Julia Wolter 5
Marco Comby 5
Feyza Sacarcelik 5
Ieva Drulyte 6
Heyrhyoung Lyoo 4
Chunyan Wang 4
Wentao Li 4
Wenjuan Du 4
H Kaspar Binz 7
Rachel Herrup 8
Sabrina Lusvarghi 8
Sabari Nath Neerukonda 8
Russell Vassell 8
Wei Wang 8
Julia M Adler 9
Kathrin Eschke 9
Mariana Nascimento 9
Azza Abdelgawad 9
Achim D. Gruber 10
Judith Bushe 10
Olivia Kershaw 10
Charles G. Knutson 11
Kamal K Balavenkatraman 12
Krishnan Ramanathan 13
Emanuel Wyler 14
Luiz-Gustavo Teixeira Alves 14
Seth Lewis 5
Randall Watson 5
Micha A Haeuptle 5
Alexander Zürcher 5
Keith M Dawson 5
Daniel Steiner 5
Carol Weiss 8
Patrick Amstutz 5
Frank J. M. van Kuppeveld 4
Michael T. STUMPP 5
Berend-Jan Bosch 4
Olivier B Engler 2
Jakob Trimpert 9
2
 
Spiez Laboratory, Austrasse, Spiez, Switzerland
5
 
Molecular Partners Ag, Zurich-Schlieren, Switzerland
6
 
Materials and Structural Analysis, Thermo Fisher Scientific, Eindhoven, Netherlands
7
 
Binz Biotech Consulting, Zug, Switzerland
11
 
Novartis Institutes for BioMedical Research, PK Sciences, Cambridge, USA
12
 
Novartis Institutes for BioMedical Research, Preclinical Safety, Basel, Switzerland
13
 
Novartis Pharma Ag, Basel, Switzerland
14
 
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
Publication typeJournal Article
Publication date2022-07-21
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor46.9
ISSN10870156, 15461696
Molecular Medicine
Applied Microbiology and Biotechnology
Biotechnology
Bioengineering
Biomedical Engineering
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with potential resistance to existing drugs emphasizes the need for new therapeutic modalities with broad variant activity. Here we show that ensovibep, a trispecific DARPin (designed ankyrin repeat protein) clinical candidate, can engage the three units of the spike protein trimer of SARS-CoV-2 and inhibit ACE2 binding with high potency, as revealed by cryo-electron microscopy analysis. The cooperative binding together with the complementarity of the three DARPin modules enable ensovibep to inhibit frequent SARS-CoV-2 variants, including Omicron sublineages BA.1 and BA.2. In Roborovski dwarf hamsters infected with SARS-CoV-2, ensovibep reduced fatality similarly to a standard-of-care monoclonal antibody (mAb) cocktail. When used as a single agent in viral passaging experiments in vitro, ensovibep reduced the emergence of escape mutations in a similar fashion to the same mAb cocktail. These results support further clinical evaluation of ensovibep as a broad variant alternative to existing targeted therapies for Coronavirus Disease 2019 (COVID-19). Multiple variants of SARS-CoV-2 are inhibited by a trispecific DARPin.

Top-30

Citations by journals

1
2
International Journal of Molecular Sciences
2 publications, 5.88%
Viruses
2 publications, 5.88%
Antiviral Research
2 publications, 5.88%
Nature Chemical Biology
1 publication, 2.94%
Frontiers in Immunology
1 publication, 2.94%
Cell Reports
1 publication, 2.94%
Nature Microbiology
1 publication, 2.94%
Nature Communications
1 publication, 2.94%
Scientific Reports
1 publication, 2.94%
Immunity
1 publication, 2.94%
Frontiers in Molecular Biosciences
1 publication, 2.94%
Molecular Therapy
1 publication, 2.94%
Proceedings of the National Academy of Sciences of the United States of America
1 publication, 2.94%
Biomaterials
1 publication, 2.94%
PLoS Pathogens
1 publication, 2.94%
Current Research in Microbial Sciences
1 publication, 2.94%
PNAS Nexus
1 publication, 2.94%
Journal of Medical Virology
1 publication, 2.94%
Nature Reviews Microbiology
1 publication, 2.94%
Clinical Pharmacology and Therapeutics
1 publication, 2.94%
FEBS Open Bio
1 publication, 2.94%
Journal of Medicinal Chemistry
1 publication, 2.94%
mBio
1 publication, 2.94%
Cancer immunology research
1 publication, 2.94%
Annual Review of Chemical and Biomolecular Engineering
1 publication, 2.94%
Expert Opinion on Drug Discovery
1 publication, 2.94%
Open Forum Infectious Diseases
1 publication, 2.94%
Russian Chemical Reviews
1 publication, 2.94%
Plant Cell Reports
1 publication, 2.94%
1
2

Citations by publishers

1
2
3
4
5
6
7
Elsevier
7 publications, 20.59%
Springer Nature
6 publications, 17.65%
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 11.76%
Wiley
3 publications, 8.82%
Frontiers Media S.A.
2 publications, 5.88%
Cold Spring Harbor Laboratory
2 publications, 5.88%
Oxford University Press
2 publications, 5.88%
Proceedings of the National Academy of Sciences (PNAS)
1 publication, 2.94%
Public Library of Science (PLoS)
1 publication, 2.94%
American Chemical Society (ACS)
1 publication, 2.94%
American Society for Microbiology
1 publication, 2.94%
American Association for Cancer Research (AACR)
1 publication, 2.94%
Annual Reviews
1 publication, 2.94%
Taylor & Francis
1 publication, 2.94%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 2.94%
1
2
3
4
5
6
7
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Rothenberger S. et al. The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants // Nature Biotechnology. 2022.
GOST all authors (up to 50) Copy
Rothenberger S. et al. The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants // Nature Biotechnology. 2022.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41587-022-01382-3
UR - https://doi.org/10.1038/s41587-022-01382-3
TI - The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
T2 - Nature Biotechnology
AU - Rothenberger, Sylvia
AU - Hurdiss, Daniel L.
AU - Walser, Marcel
AU - Malvezzi, Francesca
AU - Mayor, Jennifer
AU - Ryter, Sarah
AU - Moreno, Hector
AU - Liechti, Nicole
AU - Bosshart, Andreas
AU - Iss, Chloe
AU - Calabro, Valérie
AU - Cornelius, Andreas
AU - Hospodarsch, Tanja
AU - Neculcea, Alexandra
AU - Looser, Thamar
AU - Schlegel, Anja
AU - Fontaine, Simon
AU - Villemagne, Denis
AU - Paladino, Maria
AU - Dieter, Schiegg
AU - Mangold, Susanne
AU - Reichen, Christian
AU - Radom, Filip
AU - Kaufmann, Yvonne
AU - Schaible, Doris
AU - Schlegel, Iris
AU - ZITT, Christof
AU - Sigrist, Gabriel
AU - Straumann, Marcel
AU - Wolter, Julia
AU - Comby, Marco
AU - Sacarcelik, Feyza
AU - Drulyte, Ieva
AU - Lyoo, Heyrhyoung
AU - Wang, Chunyan
AU - Li, Wentao
AU - Du, Wenjuan
AU - Binz, H Kaspar
AU - Herrup, Rachel
AU - Lusvarghi, Sabrina
AU - Neerukonda, Sabari Nath
AU - Vassell, Russell
AU - Wang, Wei
AU - Adler, Julia M
AU - Eschke, Kathrin
AU - Nascimento, Mariana
AU - Abdelgawad, Azza
AU - Gruber, Achim D.
AU - Bushe, Judith
AU - Kershaw, Olivia
AU - Knutson, Charles G.
AU - Balavenkatraman, Kamal K
AU - Ramanathan, Krishnan
AU - Wyler, Emanuel
AU - Teixeira Alves, Luiz-Gustavo
AU - Lewis, Seth
AU - Watson, Randall
AU - Haeuptle, Micha A
AU - Zürcher, Alexander
AU - Dawson, Keith M
AU - Steiner, Daniel
AU - Weiss, Carol
AU - Amstutz, Patrick
AU - van Kuppeveld, Frank J. M.
AU - STUMPP, Michael T.
AU - Bosch, Berend-Jan
AU - Engler, Olivier B
AU - Trimpert, Jakob
PY - 2022
DA - 2022/07/21 00:00:00
PB - Springer Nature
SN - 1087-0156
SN - 1546-1696
ER -
BibTex
Cite this
BibTex Copy
@article{2022_Rothenberger,
author = {Sylvia Rothenberger and Daniel L. Hurdiss and Marcel Walser and Francesca Malvezzi and Jennifer Mayor and Sarah Ryter and Hector Moreno and Nicole Liechti and Andreas Bosshart and Chloe Iss and Valérie Calabro and Andreas Cornelius and Tanja Hospodarsch and Alexandra Neculcea and Thamar Looser and Anja Schlegel and Simon Fontaine and Denis Villemagne and Maria Paladino and Schiegg Dieter and Susanne Mangold and Christian Reichen and Filip Radom and Yvonne Kaufmann and Doris Schaible and Iris Schlegel and Christof ZITT and Gabriel Sigrist and Marcel Straumann and Julia Wolter and Marco Comby and Feyza Sacarcelik and Ieva Drulyte and Heyrhyoung Lyoo and Chunyan Wang and Wentao Li and Wenjuan Du and H Kaspar Binz and Rachel Herrup and Sabrina Lusvarghi and Sabari Nath Neerukonda and Russell Vassell and Wei Wang and Julia M Adler and Kathrin Eschke and Mariana Nascimento and Azza Abdelgawad and Achim D. Gruber and Judith Bushe and Olivia Kershaw and Charles G. Knutson and Kamal K Balavenkatraman and Krishnan Ramanathan and Emanuel Wyler and Luiz-Gustavo Teixeira Alves and Seth Lewis and Randall Watson and Micha A Haeuptle and Alexander Zürcher and Keith M Dawson and Daniel Steiner and Carol Weiss and Patrick Amstutz and Frank J. M. van Kuppeveld and Michael T. STUMPP and Berend-Jan Bosch and Olivier B Engler and Jakob Trimpert},
title = {The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants},
journal = {Nature Biotechnology},
year = {2022},
publisher = {Springer Nature},
month = {jul},
url = {https://doi.org/10.1038/s41587-022-01382-3},
doi = {10.1038/s41587-022-01382-3}
}
Found error?